Chinese expert consensus on Anlotinib Hydrochloride for advanced lung cancer (2020 edition).
10.3760/cma.j.cn112152-20200721-00669
- Collective Name:Chinese Association for Clinical Oncologists;Expert Committee of Vascular Targeted Therapy of Chinese Society of Clinical Oncology;Cancer Targeted Therapy Professional Committee of China Anti-Cancer Association
- Publication Type:Journal Article
- Keywords:
Anlotinib hydrochloride;
Consensus;
Lung neoplasms;
Therapy
- MeSH:
Carcinoma, Non-Small-Cell Lung/drug therapy*;
China;
Consensus;
Humans;
Indoles/therapeutic use*;
Lung Neoplasms/drug therapy*;
Protein Kinase Inhibitors/therapeutic use*;
Quinolines/therapeutic use*
- From:
Chinese Journal of Oncology
2020;42(10):807-816
- CountryChina
- Language:Chinese
-
Abstract:
Anlotinib hydrochloride is the only anti-angiogenic, multi-targeted tyrosine kinase inhibitor, which has been approved for non-small cell lung cancer and small cell lung cancer in China. In order to provide guidance for clinical practitioners to use anlotinib hydrochloride safely and efficiently, the Chinese Association for Clinical Oncologists, the Expert Committee of Vascular Targeted Therapy of Chinese Society of Clincal Oncology and the Cancer Targeted Therapy Professional Committee of China Anti-Cancer Association co-organized experts and integrated multiple evidences of Anlotinib Hydrochloride, from both clinical trial, post-marketed clinical data and the associated experiences of experts accumulated in clinical practice, etc. The present consensus covers the clinical data of anlotinib hydrochloride applied in advanced non-small cell lung cancer and small cell lung cancer, and the safety management recommendations.
